This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary IGF-2R Therapeutic Antibody Development
Background of IGF-2R
Considering the role of IGF-2R in regulating cell growth and the progression of companion animal cancers, it is seen as a promising therapeutic target in the field of veterinary medicine. BioVenic offers veterinary therapeutic development services targeting IGF-2R, relying on emerging technologies in antibody preparation, engineering, and so on, dedicated to assisting in advancing the treatment of companion animal cancers.
Background of IGF-2R
| Full Name | Insulin-like growth factor 2 receptor |
|---|---|
| Aliases | CD222, CI-M6PR, CIMPR, M6P-R, M6P/IGF2R, MPR 300, MPR1, MPR300, MPRI. |
| Target Profile | Insulin-like growth factor 2 receptor (IGF-2R), also known as cation-independent mannose 6-phosphate (CI-M6P) is the transmembrane glycoprotein, composed of a large extracellular N-terminal domain and lacking tyrosine kinase activity. This receptor has multiple functions, including the intracellular transport of lysosomal enzymes, the activation of TGF-β, and the degradation of IGF-2. |
MoA of IGF-2R
By binding to IGF-2, IGF-2R serves to regulate its intracellular concentration, preventing the interaction with IGF-1R, and causing its internalization and degradation in lysosomes. In this way, IGF-2R controls the signaling pathways activated by IGF-2, which are involved in cell proliferation, growth, and survival. IGF-2R is also associated with the activation of TGF-β, the cytokine that regulates cell proliferation, differentiation, and apoptosis. Once TGF-β is activated and interacts with the receptor, it phosphorylates TACE/ADAM17 via the MAPK pathway and translocates it to the cell membrane, thereby permitting the cleavage of IGF-2R.
Fig.1 Schematic diagram of the IGF-2R role in IGF axis.1
Application in Veterinary Therapeutics
IGF-2R isolates and internalizes IGF-2 for degradation, and is also considered a tumor suppressor. It has been found to be overexpressed in canine osteosarcoma, and sequence alignment reveals that IGF-2R is highly conserved. IGF-2R expression is both significant and related to the development of certain types of cancers in companion animals, making it an ideal therapeutic target. IGF-2R Therapeutic antibodies bind specifically to IGF-2R, preventing the interaction with IGF-2, reducing related signaling, and holding the potential to inhibit tumor cell proliferation and survival. Additionally, inhibiting IGF-2R may affect tumor angiogenesis, thus weakening tumor blood supply and growth.
Veterinary IGF-2R Therapeutic Antibody Development Services
To support research targeting IGF-2R, an important receptor in companion animal cancers, BioVenic offers veterinary IGF-2R therapeutic antibody development services. Our services encompass the entire antibody development process, from antibody design and characterization to engineering optimization, meeting project development needs, and ensuring the suitability of these veterinary therapeutic antibodies for companion animal cancer research.
For more information about our veterinary IGF-2R therapeutic antibody development services, please click the link below.
Why Choose Us?
We offer a variety of veterinary therapeutic antibody development technologies, including hybridoma, single B cell, and phage display techniques.
Our services include structural and functional characterization of antibodies, ensuring the high quality of the veterinary therapeutic antibodies we assist in developing.
We provide species-specific antibody development services and include affinity maturation in our antibody engineering to ensure the therapeutic efficacy of the candidate antibodies.
Blocking the IGF-2R signaling pathway has the potential to effectively inhibit the occurrence, development, and metastasis of animal tumors. BioVenic offers veterinary therapeutic antibody development services for IGF-2R, assisting you in exploring tumor treatment solutions for companion animals like feline, canine and equine. If you have such needs, please contact us immediately.
References
- Tian, Zhennan, et al. "IGF2R expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC." Cellular Physiology and Biochemistry 34.5 (2014): 1578-1588.
- Castro, Juan José, et al. "DHA Supplementation during Pregnancy in Women with Obesity Normalizes IGF2R Levels in the Placenta of Male Newborns." International Journal of Endocrinology 2023 (2023).
- Boisclair, Charles, et al. "Characterization of IGF2R Molecular Expression in Canine Osteosarcoma as Part of a Novel Comparative Oncology Approach." International Journal of Molecular Sciences 24.3 (2023): 1867.